@article{7a66ac0652554bbb97ee5121a9793cff,
title = "Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases",
abstract = "Lysophosphatidic acid (LPA) acts through high-affinity G protein-coupled receptors to mediate a plethora of physiological and pathological activities associated with tumorigenesis. LPA receptors and autotaxin (ATX/LysoPLD), the primary enzyme producing LPA, are aberrantly expressed in multiple cancer lineages. However, the role of ATX and LPA receptors in the initiation and progression of breast cancer has not been evaluated. We demonstrate that expression of ATX or each edg family LPA receptor in mammary epithelium of transgenic mice is sufficient to induce a high frequency of late-onset, estrogen receptor (ER)-positive, invasive, and metastatic mammary cancer. Thus, ATX and LPA receptors can contribute to the initiation and progression of breast cancer.",
keywords = "CELLCYCLE",
author = "Shuying Liu and Makiko Umezu-Goto and Mandi Murph and Yiling Lu and Wenbin Liu and Fan Zhang and Shuangxing Yu and Stephens, {L. Clifton} and Xiaojiang Cui and George Murrow and Kevin Coombes and William Muller and Hung, {Mien Chie} and Perou, {Charles M.} and Lee, {Adrian V.} and Xianjun Fang and Mills, {Gordon B.}",
note = "Funding Information: We are grateful to S. Tsai (Baylor College of Medicine) for providing MMTV-KCR (BS) vector; K.W. Cheng (MD Anderson Cancer Center) for providing pcDNA3.0- FLAG - lpa1 , 2 , and 3 vectors; D. Siwak (MD Anderson Cancer Center) for technical assistance on RPPA; T. Clair (National Cancer Institute) for providing pcDNA3.1- atx/LysoPLD vector; T.J. Aoki (The University of Tokyo) for providing anti-ATX antibody; and O. Britton (Breast Center, Baylor College of Medicine) for technical assistance on whole mount. The work was supported by DOD Breast Cancer Research Program DAMD17-03-1-0409 (to S.L.), by National Institute of Health Grants CA82716, CA64602, and CA099031 (to G.B.M.), and CA94118 (to A.V.L.), by a Breast Cancer Research Foundation Grant (to G.B.M.), by sponsored research to M.M. from LPATH Biotechnologies, and by National Institute of Health Core Grant P30 CA016672. Lpath Therapeutics, Inc. sponsored research to G.B.M. and M.M. G.B.M. is a stockholder in Lpath Therapeutics, Inc. ",
year = "2009",
month = jun,
day = "2",
doi = "10.1016/j.ccr.2009.03.027",
language = "English (US)",
volume = "15",
pages = "539--550",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "6",
}